PDCD1 and neoplasm: The subgroup analysis of PD-L1 expression levels showed an apparently greater magnitude of OS and PFS benefits of anti-PD-1/PD-L1 treatment over docetaxel in patients with higher tumor PD-L1 expression than in the overall population, while the benefit was not seen in patients with low PD-L1 expression, irrespective of the cut-off used.